Skip to content

Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)

Incidence of Urinary Retention in Patients Undergoing Unilateral Total Knee Arthroplasty- Comparison Between Continuous Epidural Analgesia and Single Shot Femoral Nerve Block- a Randomized Controlled Study (UriKANE)

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02689011
Acronym
UriKANE
Enrollment
60
Registered
2016-02-23
Start date
2014-01-31
Completion date
2015-01-31
Last updated
2016-02-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Pain, Post Operative Pain, Urinary Retention

Keywords

Total Knee Arthroplasty, Femoral Nerve Block, Epidural Analgesia, Urinary Retention, Lumbar Epidural

Brief summary

This study aims to compare the incidence of urinary retention and requirement of bladder catheterization in patients undergoing total knee arthroplasty while receiving either continuous epidural analgesia or single shot femoral nerve block.

Interventions

PROCEDUREFemoral Nerve Block

For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve

PROCEDUREEpidural

Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.

Sponsors

Aga Khan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
30 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* ASA Physical status I, II & III * Male and Female Patients age between between 30 and 70 years * Unilateral Total Knee Arthroplasty

Exclusion criteria

* Patient Refusal * Allergy to local anesthetics, paracetamol or other study drugs * History of opioid dependence * Contraindications to spinal/epidural anesthesia and femoral nerve block (coagulation defects, infection at puncture site etc.) * Inability to use patient-controlled analgesia (IV PCIA) (as assessed at the time of informed consent) * History of urinary retention, neurogenic bladder, or any urologic problem

Design outcomes

Primary

MeasureTime frameDescription
Incidence of urinary retention24 HoursTo compare the incidence of urinary retention in patients undergoing unilateral Total Knee Arthroplasty receiving continuous epidural analgesia vs. single shot Femoral Nerve Block.

Secondary

MeasureTime frameDescription
Mean post-operative sedation scoresup to 48 hoursTo compare the mean post-operative sedation scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
Mean post-operative pain scoresup to 48 hoursTo compare the mean post-operative pain scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
Surgical outcomes - maximal knee flexionup to 48 hoursTo compare surgical outcomes like maximal knee flexion at 24 & 48 hours between the two groups
Mean post-operative nausea and vomiting scoresup to 48 hoursTo compare the mean post-operative nausea and vomiting scores between the two groups at 0, 1, 12, 24 & 48 hours postoperatively.
Surgical outcomes - mobilization out of bedup to 48 hoursTo compare surgical outcomes like time taken to mobilize out of bed between the two groups
Surgical outcomes - food intakeup to 48 hoursTo compare surgical outcomes like time of first food intake between the two groups
Patient satisfaction7 DaysTo compare Patient satisfaction with the analgesic modality between the two groups
Surgical outcomes - duration of post-operative hospital stayup to 48 hoursTo compare surgical outcomes like duration of post-operative hospital stay between the two groups

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026